- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07038148
- Original rettssak
Single-Stage Stapled Conversion of Gastric Bypass to Sleeve Gastrectomy
Exploring the Efficacy of Single Stage Stapled Conversion of Gastric Bypass to Sleeve Gastrectomy, More Leak?
Some patients who have had a gastric bypass (Roux-en-Y gastric bypass or one anastomosis gastric bypass) develop long-term problems such as nutritional deficiencies, intractable dumping syndrome, retrograde intussusception or weight regain, and some cannot afford the lifelong vitamin supplements the bypass requires. When these problems do not respond to non-surgical treatment, the bypass can be reversed to normal anatomy, but many patients refuse reversal because they fear regaining weight. Converting the bypass to a sleeve gastrectomy is an alternative that restores food passage through the duodenum while keeping a restrictive operation.
This single-arm study evaluates the efficacy, safety and patient outcomes of single-stage laparoscopic stapled conversion of gastric bypass to sleeve gastrectomy in adults at Kasr Al-Ainy hospitals, Cairo University. Patients are followed for 6 months after surgery for nutritional status, weight regain, quality of life, reflux (GERD) symptoms and postoperative complications, including leak.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Background: Laparoscopic gastric bypass, including Roux-en-Y gastric bypass (RYGB) and one anastomosis gastric bypass (OAGB), is one of the most frequently performed metabolic bariatric procedures. As the number of bypass operations increases, complications are reported more often. Most can be managed non-surgically, but a small number of persistent cases require reversal to normal anatomy or conversion to another procedure. Complications that may require conversion include retrograde intussusception, weight regain, intractable dumping syndrome and nutritional deficiencies; the high cost of obligatory postoperative vitamins is a further reason for conversion in low-income countries. Conversion is technically demanding, carries a relatively higher rate of postoperative complications, and data on its outcomes are limited.
Design: Prospective, single-arm interventional study.
Preoperative assessment: Patients attending the bariatric outpatient clinic who meet the eligibility criteria are enrolled after patient education. History, anthropometric measures, chronic diseases and previous surgeries are recorded. Routine preoperative laboratory tests and imaging are performed, together with a preoperative 3D CT gastric volumetry.
Surgical technique: After pneumoperitoneum and laparoscopic port placement, the previous gastrojejunostomy is closed with an endostapler applied across the anastomosis and fired on the jejunal side. The end of the gastric pouch is then anastomosed to the remnant stomach with an endostapler. A 36 Fr orogastric tube is passed through the anastomosis as a guide, and a sleeve gastrectomy is performed by resecting the stomach along the greater curvature with endostaplers. An intraoperative methylene blue leak test is performed, hemostasis along the staple line is confirmed, and all ports are closed.
Postoperative care and follow-up: Patients stay in hospital for about 24 hours for monitoring of vital signs and the feeding regimen. Nutritional laboratory parameters (hemoglobin, ferritin, vitamin D, zinc, magnesium, serum albumin and calcium), quality of life (Bariatric Quality of Life Index) and GERD symptoms (GERD-HRQL questionnaire) are assessed at 3 and 6 months after surgery. Body weight is recorded monthly to assess weight regain.
Sample size: Calculated with the ClinCalc sample size calculator (alpha 0.05, power 0.80) as 11 patients, including 10% to cover loss to follow-up. A convenience sample of eligible patients is enrolled until this number is reached.
Statistical analysis: SPSS version 21. Categorical data as number and percentage; quantitative data as mean and standard deviation or median and interquartile range. Chi-square, Student t and Mann-Whitney tests, with correlation and regression analysis. Significance at p of 0.05 or less.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Cairo, Egypt
- Kasr Alaini Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18 to 70 years
- Adult patients with a previous gastric bypass undergoing single-stage laparoscopic stapled conversion of gastric bypass to sleeve gastrectomy
Exclusion Criteria:
- Reversal of gastric bypass to normal anatomy
- Uncontrolled systemic disease
- Active psychological disorder
- Intraoperative technical difficulties preventing conversion of gastric bypass to sleeve gastrectomy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Conversion to sleeve gastrectomy
Adults with a previous gastric bypass (RYGB or OAGB) undergoing single-stage laparoscopic stapled conversion to sleeve gastrectomy. |
Stapled closure of the previous gastrojejunostomy on the jejunal side, stapled anastomosis of the gastric pouch to the remnant stomach, then sleeve gastrectomy along the greater curvature over a 36 Fr orogastric tube, with an intraoperative methylene blue leak test. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative leak
Tidsramme: From surgery up to 6 months after surgery
|
Number of participants with a staple-line or anastomotic leak after single-stage stapled conversion of gastric bypass to sleeve gastrectomy. |
From surgery up to 6 months after surgery
|
|
Change in nutritional status
Tidsramme: Preoperatively, and at 3 and 6 months after surgery
|
Nutritional status assessed with laboratory parameters: hemoglobin, serum ferritin, vitamin D, zinc, magnesium, serum albumin and calcium. |
Preoperatively, and at 3 and 6 months after surgery
|
|
Weight regain
Tidsramme: Monthly from surgery up to 6 months after surgery
|
Body weight (kg) recorded monthly after conversion to assess weight regain. |
Monthly from surgery up to 6 months after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of life (Bariatric Quality of Life Index)
Tidsramme: 3 and 6 months after surgery
|
Quality of life assessed with the Bariatric Quality of Life (BQL) Index. |
3 and 6 months after surgery
|
|
GERD symptoms (GERD-Health Related Quality of Life questionnaire)
Tidsramme: 3 and 6 months after surgery
|
Gastroesophageal reflux symptoms assessed with the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire. |
3 and 6 months after surgery
|
|
Other postoperative complications
Tidsramme: From surgery up to 6 months after surgery
|
Number of participants with postoperative complications other than leak, including bleeding and stricture. |
From surgery up to 6 months after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ahmed Mohamed Abdelsalam, MD, Cairo University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Postoperative komplikasjoner
- Patologiske prosesser
- Ernæringsforstyrrelser
- Overernæring
- Kroppsvekt
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Overvektig
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Postgatrektomi syndromer
- Overvekt
- Dumping syndrom
Andre studie-ID-numre
- N-8-2025
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .